MRS is capable of displaying minute distinctions in the magnetic properties of different chemical compounds to provide a unique biochemical signature. Related StoriesUT Southwestern's Helen H. Hobbs named recipient of Breakthrough Prize in Life SciencesHDL not so good in protecting ladies against atherosclerosis, research showsLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. KlegermanAegerion Pharmaceuticals is a biopharmaceutical company centered on the advancement and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic disease.Although persons with detectable mutations had a markedly increased risk of hematologic cancer, the complete risk remained small; general, a hematologic cancers developed during the study period in approximately 4 percent of individuals with a mutation . This means a risk of hematologic cancer of 0 approximately.5 percent per year overall and approximately 1 percent per year among persons with a variant allele fraction greater than 0.10. However, we were unable to evaluate the hematologic cancers to assess the relationship of the tumor to the mutant clone that preceded it.